This is a Phase I, open-label dose-escalation study of AC682, an orally available estrogen receptor degrader, given as a single agent.
This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to:~To evaluate the safety and tolerability of AC682~To evaluate the pharmacokinetic of AC682~To evaluate the preliminary anti-tumor activity of AC682